New pill BTM-3566 takes on tough lymphoma in early trial

NCT ID NCT06792734

Recruiting now Disease control Sponsor: Bantam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This early-phase trial is testing an oral drug called BTM-3566 in 24 adults with relapsed or refractory B-cell lymphoma. The main goals are to find a safe dose and see if the drug can slow or stop the cancer. Participants take the drug for 7 days, then have 7 days off, and visit the clinic regularly for checkups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BTM-3566 (an oral drug)
What this could lead to: If it works, this could point toward a new treatment option for people with B-cell lymphoma that has not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 24 participants, so the main goal is safety, not effectiveness. The drug may cause side effects or not work well enough to move forward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA, B-CELL

Contacts and locations

Locations

Levine Cancer Institute, Atrium Health
RECRUITING

Charlotte, North Carolina, 28204, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.